NanoBio® Corporation is a biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStatTM technology platform. This technology has the potential for facilitating a wide range of products including nasal spray vaccines.
Heading Nanobio is CSO and researcher/inventor James R. Baker, Jr., MD. Dr. Baker is the Ruth Dow Doan Professor at the University of Michigan's School of Medicine and Chief of the Division of Allergy. He also is the Director of the U of M Nanotechnology Institute for Medicine and Biomedical Studies (M-NIMBS).
Through 2006 NanoBio's NanoStat technology recieved $31 million in investments through grants and angel investors. An additional $30 million was secured via private equity funding from Perseus LLC
NanoBio's commercial product pipeline consists of six promising pharmaceuticals, including two leading treatments for cold sores and nail fungus as well as medicines that target genital herpes, herpes zoster (shingles), and methicillin resistant Staphylococcus aureus (MRSA).
In addition, a vaccine prototype based on the NanoStatTM platform is being developed by M-NIMBS. This effort is funded by a $6.3 million grant.
With a dozen employees, the company is looking to grow to 20 to 25 positions over the next year.